Literature DB >> 12898541

Hyperalgesic effects of gamma-aminobutyric acid transporter I in mice.

Jia-Hua Hu1, Na Yang, Ying-Hua Ma, Xiao-Gang Zhou, Jie Jiang, Shu-Hui Duan, Zhen-Tong Mei, Jian Fei, Li-He Guo.   

Abstract

The present study focused on the involvement of gamma-aminobutyric acid transporter I (GAT1) in pain. We found that GABA uptake was increased in mouse spinal cord at 20 min and 120 min after formalin injection and in mouse brain at 120 min, but not 20 min, after formalin injection. In addition, the antinociceptive effects of GAT1-selective inhibitors were examined using assays of thermal (tail-flick) and chemical (formalin and acetic acid) nociception in C57BL/6J mice. The GAT1-selective inhibitors, ethyl nipecotate and NO-711, exhibited significant antinociceptive effects in these nociceptive assays. To study further the effects of GAT1 on pain, we used two kinds of GAT1-overexpressing transgenic mice (under the control of a CMV promoter or a NSE promoter) to examine the nociceptive responses in these mice. In the thermal, formalin, and acetic acid assays, both kinds of transgenic mice displayed significant hyperalgesia after nociceptive stimuli. In addition, the micro opioid receptor antagonist naloxone had no influence on nociceptive responses in wild-type and transgenic mice. The results indicate that GAT1 is involved in the regulation of pain processes, and point to the possibility of developing analgesic drugs that target GAT1 other than opioid receptors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898541     DOI: 10.1002/jnr.10677

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  10 in total

1.  Are spinal GABAergic elements related to the manifestation of neuropathic pain in rat?

Authors:  Jaehee Lee; Seung Keun Back; Eun Jeong Lim; Gyu Chong Cho; Myung Ah Kim; Hee Jin Kim; Min Hee Lee; Heung Sik Na
Journal:  Korean J Physiol Pharmacol       Date:  2010-04-30       Impact factor: 2.016

2.  Acupuncture: Emerging evidence for its use as an analgesic (Review).

Authors:  Peng Gao; X I Gao; Tairan Fu; Dan Xu; Qingping Wen
Journal:  Exp Ther Med       Date:  2015-03-12       Impact factor: 2.447

Review 3.  Stress-induced pain: a target for the development of novel therapeutics.

Authors:  Anthony C Johnson; Beverley Greenwood-Van Meerveld
Journal:  J Pharmacol Exp Ther       Date:  2014-09-05       Impact factor: 4.030

4.  Blocking the GABA transporter GAT-1 ameliorates spinal GABAergic disinhibition and neuropathic pain induced by paclitaxel.

Authors:  Ruchi Yadav; Xisheng Yan; Dylan W Maixner; Mei Gao; Han-Rong Weng
Journal:  J Neurochem       Date:  2015-04-23       Impact factor: 5.372

5.  Transmission pathways and mediators as the basis for clinical pharmacology of pain.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Tyler A Smith; Nicholas P Dueck; Mitchell J Kerfeld; Zakary J Hambsch; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-07-04       Impact factor: 5.045

Review 6.  Reviewing the case for compromised spinal inhibition in neuropathic pain.

Authors:  M A Gradwell; R J Callister; B A Graham
Journal:  J Neural Transm (Vienna)       Date:  2019-10-22       Impact factor: 3.575

Review 7.  Glial cells and chronic pain.

Authors:  Romain-Daniel Gosselin; Marc R Suter; Ru-Rong Ji; Isabelle Decosterd
Journal:  Neuroscientist       Date:  2010-06-25       Impact factor: 7.519

Review 8.  GABA and central neuropathic pain following spinal cord injury.

Authors:  Young S Gwak; Claire E Hulsebosch
Journal:  Neuropharmacology       Date:  2011-01-07       Impact factor: 5.250

9.  Comprehensive analysis of the GABAergic system gene expression profile in the anterior cingulate cortex of mice with Paclitaxel-induced neuropathic pain.

Authors:  Willias Masocha
Journal:  Gene Expr       Date:  2015

10.  Inhibition of Activity of GABA Transporter GAT1 by δ-Opioid Receptor.

Authors:  Lu Pu; Nanjie Xu; Peng Xia; Quanbao Gu; Shuanglai Ren; Thomas Fucke; Gang Pei; Wolfgang Schwarz
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-25       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.